Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Acute and Two-week Effects of Spiolto® Respimat® (Tiotropium/Olodaterol) on Cardiac Function, the Autonomic Nervous System and Small Airway Function in Hyperinflated COPD Subjects

NCT04231214 is registered in ClinicalTrials.gov with Fraunhofer-Institute of Toxicology and Experimental Medicine as lead sponsor.

NCT NCT04231214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04231214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Acute and Two-week Effects of Spiolto® Respimat® (Tiotropium/Olodaterol) on Cardiac Function, the Autonomic Nervous System and Small Airway Function in Hyperinflated COPD Subjects
Lead sponsor
Fraunhofer-Institute of Toxicology and Experimental Medicine
Phase
Phase 4
Overall status
Completed
Start date
January 28, 2020
Completion date
April 18, 2023
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease